"It's a hassle to manually create the same Excel file every month," or "I want to eliminate the task of copying and pasting data to update charts"—you can automate these repetitive tasks with Python.

We've tested the top AI image generation apps to help you find the one that produces the best results for the lowest price. I’ve been writing about consumer technology and video games for more than a ...

Many small businesses store customer and invoice data in Excel. Creating invoices one by one is slow and easy to get wrong. This tool turns Excel rows into clean PDF invoices automatically.

In the previous article, I created a tool to record income and expenses and visualize them with graphs. This time, I'm talking about adding Phase 2: A feature to automatically output invoices and ...

Driving an RV lets you bring the comforts of home along on your road trip, but having a portable generator is essential. It powers your electric appliances and charges electronics, like your phone and ...

Tax season is nigh upon us, and this year there is a meaningfully different option for the millions of Kenyan traders who have long found eTIMS too technical, too slow, or simply too much to deal with ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...